Evidence map›Paper›PMID 38154488›Full record

ArticleMedical mycology2024

The Nairobi Declaration 2023: A commitment to address deadly yet neglected fungal diseases in Africa.

Iriagbonse I Osaigbovo, Nelesh P Govender, Alexander M Jordan, Felix Bongomin, David B Meya, Alice Kanyua, Olga M Mashedi, David Koffi, Angela Loyse, Aude Sturny-Leclère and 5 more

Open access · bronzeAbstract read
In one paragraph

Article in Medical mycology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
1.4field-weighted citation impact, top 19% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 7 citations in OpenAlex.

  1. A review of the current anti-New microbes and new infections · 2026
    Review
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 14 institutions in 10 countries.

Iriagbonse I OsaigbovoDepartment of Medical Microbiology, School of Medicine, College of Medical Sciences, University of Benin, Benin City, Nigeria.ORCID 0000-0001-8111-0743
Nelesh P GovenderNational Institute for Communicable Diseases, a Division of the National Health Laboratory Service, School of Pathology, University of the Witwatersrand, Johannesburg, South Africa.ORCID 0000-0001-7869-9462
Alexander M JordanMycotic Diseases Branch, Division of Foodborne, Waterborne, and Environmental Diseases, Centers for Disease Control and Prevention, Atlanta, United States of America.
Felix BongominDepartment of Medical Microbiology and Immunology, Faculty of Medicine, Gulu University, Gulu, Uganda.ORCID 0000-0003-4515-8517
David B MeyaInfectious Diseases Institute, Makerere University, Kampala, Uganda.ORCID 0000-0002-8854-0321
Alice KanyuaDepartment of Pathology and Laboratory Medicine, Aga Khan University, Nairobi, Kenya.ORCID 0000-0002-8241-5845
Olga M MashediKenya Medical Research Institute, Nairobi, Kenya.
David KoffiInstitut Pasteur de Côte d'Ivoire, Abidjan, Cote d'Ivoire.
Angela LoyseDivision of Infection and Immunity Research Institute, St George's University of London, London, United Kingdom.ORCID 0000-0001-7853-1344
Aude Sturny-LeclèreInstitut Pasteur, Universite Paris Cite, National Reference Center for Invasive Mycoses and Antifungals, Translational Mycology research group, Mycology Department, F-75015, Paris, France.
Jean-Pierre GangneuxCHU de Rennes, University of Rennes, INSERM, Irset (Institut de recherche en santé, environnement et travail) - UMR_S 1085, Rennes, France.ORCID 0000-0002-4974-5607
David W DenningManchester Fungal Infection Group, Division of Evolution, Infection and Genomics, Faculty of Biology, Medicine and Health, University of Manchester, Manchester Academic Health Sciences Centre, Manchester, United Kingdom.ORCID 0000-0001-5626-2251
Tom ChillerMycotic Diseases Branch, Division of Foodborne, Waterborne, and Environmental Diseases, Centers for Disease Control and Prevention, Atlanta, United States of America.
Oliver A CornelyDepartment of Internal Medicine, European Diamond Excellence Center of Medical Mycology, University Hospital Cologne, Cologne, Germany.ORCID 0000-0001-9599-3137
Rita O OladeleDepartment of Medical Microbiology and Parasitology, Faculty of Basic Medical Sciences, College of Medicine, University of Lagos, Lagos, Nigeria.ORCID 0000-0003-1488-3345
Centers for Disease Control and Prevention · USAga Khan University · PKGulu University · UGInfectious Diseases Institute · UGInserm · FRInstitut de Myologie · FRInstitut Pasteur de Côte d'Ivoire · CIKenya Medical Research Institute · KEManchester Academic Health Science Centre · GBNational Health Laboratory Service · ZASt George's, University of London · GBUniversity Hospital Cologne · DEUniversity of Benin · NGUniversity of Lagos · NG

Funding

Improving Diagnostics and Neurocognitive Outcomes in HIV/AIDS-related MeningitisR01NS086312 · NINDS · UNIVERSITY OF MINNESOTA · PI David R Boulware, David Bisagaya Meya · 2013 to 2026
$8.3M
NINDS NIH HHS R01 NS086312
6 · The paper itself

Abstract

On May 30th and 31st, 2023, delegates representing various African subregions, together with global representatives from the International Society of Human and Animal Mycology (ISHAM), the European Confederation of Medical Mycology (ECMM), the United States Centre for Disease Control and Prevention (CDC), and Global Action for Fungal Infections (GAFFI), convened in Nairobi, Kenya under the aegis of the Pan African Mycology Working Group, a working group of ISHAM. The meeting objectives were, amongst others, to deliberate on a continental response to the World Health Organisation Fungal Priority Pathogen List and facilitate interaction between global and regional leaders. Country delegates and international speakers addressed Africa's fungal disease burden; capacity for diagnosis and management; ongoing surveillance; knowledge gaps and trends in invasive fungal diseases such as Candida auris, mucormycosis, aspergillosis, and Acquired Immune Deficiency Syndrome (AIDS)-related mycoses; and current laboratory practice. During the technical sessions, expert panels deliberated on establishing and financing of national/regional surveillance networks for mycoses; establishing and sustaining African-led collaborations; expanding on existing laboratory and point-of-care diagnostic capacity as well as planning a mycology reference laboratory service and network in Africa. The meeting also highlighted successful African-led collaborations, capacity building, and clinical trial initiatives. The meeting conclusions informed the resolutions of the Nairobi Declaration calling for improved awareness; strong collaborations between clinical and laboratory teams across Africa; improved fungal disease surveillance within the continent; access to antifungals and diagnostics; and leveraging qualified human resources for mycology present within and outside Africa to facilitate trainings, collaborations, and exchanges.

Indexed as

Invasive Fungal InfectionsMucormycosisMycosesAntifungal AgentsHumansKenyaAntifungal AgentsAfricaantifungalAspergillusCandidalaboratory

Identifiers

PMID38154488
PMCPMC13048867
OpenAlexW4390372604

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.